Activating mutations in the RET proto-oncogene are associated with both familial and sporadic medullary thyroid carcinoma (MTC) development; however, the genetic mechanisms underlying MTC tumorigenesis remain largely unknown. Recently, we have identified somatic inactivating mutations in the cell cycle inhibitor gene P18 in human MTC, which coincided with activating RET mutations, suggesting a role for loss of P18 in combination with oncogenic RET in the multistep process of MTC development. Therefore, we crossed transgenic mice expressing oncogenic RET (RET2B) with mice lacking p18 (and p27, another cell cycle inhibitor) and monitored MTC development. RET2B;p18 +/À mice and RET2B;p18 À/À mice developed MTC with a highly increased incidence compared with their corresponding single mutant littermates. In addition, expression of oncogenic RET causes an earlier age of onset and larger MTCs in p18
Introduction
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominantly inherited cancer syndrome, which is mainly characterized by a combination of medullary thyroid carcinoma (MTC) and adrenal pheochromocytoma. MEN2 can be subdivided into MEN2A, MEN2B, and familial MTC. Familial MTC patients solely develop MTC, whereas MEN2A and MEN2B patients may develop, in addition to MTC and pheochromocytoma, other tumors like parathyroid adenomas ( for MEN2A) and mucosal ganglioneuromas ( for MEN2B). MTC originates from the calcitonin-producing neuroendocrine C-cells in the thyroid gland (1).
MEN2 is caused by activating germ-line mutations in the RET proto-oncogene, which encodes a transmembrane receptor tyrosine kinase (2) . RET mutations associated with MEN2 lead to constitutive activation of RET (3, 4) . A strong genotype-phenotype correlation has been described for RET and MEN2 (5, 6) . In MEN2A, the mutations affect cysteine residues in the extracellular domain of the protein (2) . In MEN2B, the most common (95%) mutation results in a Met!Thr substitution at position 918 in the intracellular domain of the protein. The M918T mutation is also found as a somatic mutation in about 30% to 40% of sporadic MTC cases (2) .
Previously, we generated transgenic mice expressing the human RET oncogene with the M918T mutation in the thyroid C-cells (RET2B; ref. 7) . MTCs were detected in only 13% (3 of 23) of these mice at 11 to 24 months of age, whereas C-cell hyperplasia (CCH), a premalignant stage of MTC, was observed in 77% of these mice from 8 months onward. The incomplete penetrance and variable latency period for MTC development in these mice, together with the clinical observation that carriers of the same germ-line RET mutation, can develop MTC at widely varying ages, suggesting that in addition to the mutated RET gene, other tumorigenic events are required for the development of MTC.
In human MTC, both hereditary and sporadic, the most frequently detected chromosomal alteration is loss of a specific part or the entire short arm of chromosome 1, with the most common break point on 1p32 (8) (9) (10) , where the candidate tumor suppressor gene CDKN2C ( from here on indicated as P18) is located. Recently, we have detected several somatic inactivating mutations in P18 in a subset of human MTCs, indicating that P18 is a tumor suppressor gene involved in human MTC development. 4 
p18
À/À mice develop CCH and MTC, the incidence of which is enhanced by additional loss of another cell cycle inhibitor (i.e., p27; ref.
11). Both cell cycle inhibitors p18
Ink4c , a member of the INK4 family, and p27 Kip1 , a member of the CIP/KIP family, inhibit the formation of active cyclin-dependent kinase (CDK) complexes and thus prevent phosphorylation of Rb1, a major player in G 1 -S phase transition (12, 13) . Interestingly, p27 knockout mice as well as Rb1 knockout mice also develop CCH and MTC, indicating that the CDK-Rb pathway is involved in the tumorigenesis of MTC (11, (14) (15) (16) . Moreover, somatic RET mutations have been described in MTC of Rb1;p53 knockout mice (17) , suggesting a cooperative effect of oncogenic RET and the Rb pathway in MTC tumorigenesis.
Because of the development of MTC in both RET2B transgenic mice and p18, p27 and p18;p27 knockout mice, together with the simultaneous occurrence of activating RET mutations and inactivating P18 mutations in human MTCs, we hypothesized that p18 and/or p27 may collaborate with oncogenic RET in the multistep tumorigenesis of MTC. To address this hypothesis, we crossed RET2B mice with p18 +/À ;p27 +/À mice and monitored MTC development. Our results indicate a strong synergistic effect of oncogenic RET and loss of p18 on MTC development and progression.
Materials and Methods
Mouse strains and genotyping. All experiments with mice were done with the approval of the Animal Experimental and Ethics Committee of the University of Utrecht, Utrecht, the Netherlands. RET2B transgenic mice (C57BL/6 background) and p18;p27 knockout mice (C57BL/6 background) were previously described (7, 11, 18) . For genotype verification, genomic tail-DNA was isolated with Prot-K lysis buffer [100 mmol/L Tris (pH 8), 5 mmol/L EDTA, 0.2% SDS, 0.2 mol/L NaCl, 100 Ag/AL proteinase K] at 55jC. Separate PCRs were done for RET, p18, and p27 using primers listed in Supplementary Table S1 . All PCRs were done at an annealing temperature of 55jC for 33 cycles.
Plasma calcitonin measurements. Blood was collected every 3 months via orbital puncture after isofloran anesthesia. Plasma was isolated from EDTA-blood by centrifugation. Plasma calcitonin concentrations were measured using a solid-phase, enzyme-labeled, two-site chemiluminescent immunometric assay (Siemens Diagnostics) with an Immulite 1000 analyzer according to the manufacturer's protocol. Interassay variability (measured over 18 assays) shows that this assay is very sensitive and robust: average concentration for assay-control 1, 11.2 pg/mL (SD, 0.27 pg/mL); variation coefficient, 2.42%; average concentration for assay-control 2, 209.5 pg/mL (SD, 3.99 pg/mL); variation coefficient, 1.90%. Plasma calcitonin levels were measured in counts per second (cps) and calculated to picograms according to the assay standard curve. Wild-type non-MTC-bearing mice have undetectable plasma calcitonin levels (f35,000 cps). Histologic analysis revealed that in our study, plasma calcitonin levels z1.4 pg/mL (z100,000 cps) indicated microscopically detectable MTCs.
Tissue processing and immunohistochemistry. Isolated thyroid tissues were fixed in 4% formaldehyde (Klinipath) overnight, dehydrated, and embedded in paraffin. Immunohistochemistry [for calcitonin, p18
Ink4c , p27 Kip1 , and proliferating cell nuclear antigen (PCNA)] was done on paraffin sections of 6 Am. For p27 Kip1 and PCNA staining, antigen unmasking was done by boiling the slides in sodium citrate buffer (10 mmol/L sodium citrate trisodium salt dihydrate in distilled water, pH 6) for 15 min. Primary antibodies used were rabbit polyclonal anti-calcitonin antibody (DAKO), diluted 1:5,000; rabbit polyclonal anti-p18 antibody (M-168; Santa Cruz Biotechnology), diluted 1:50; mouse monoclonal anti-KIP1 antibody (BD Transduction Laboratories), diluted 1:500; and mouse monoclonal anti-PCNA antibody (PC10; Cell Signaling Technology), diluted 1:4,000. Secondary antibodies used were horseradish peroxidase (HRP)-conjugated swine anti-rabbit antibody (DAKO) and HRP-conjugated rabbit anti-mouse antibody (DAKO), diluted 1:100, at room temperature for 30 min. For p27 Kip1 staining, goat anti-M/R/Ra IgG DVDPO-500H (Powervision; ImmunoLogic) was used as secondary antibody. After 3,3 ¶-diaminobenzidine precipitation, a hematoxylin counterstaining was done. The anti-KIP1 antibody and Powervision were kindly provided by the Department of Pathology of the University Medical Center Utrecht, Utrecht, the Netherlands.
Laser capture microdissection. Laser capture microdissection was used to obtain cell populations of selected areas from paraffin-embedded tissue sections. Sections Loss of heterozygosity analysis and somatic mutation analysis. For p18 loss of heterozygosity (LOH) analysis and p18 and RET mutation analysis, PCRs were done directly on DNA lysates isolated by laser capture microdissection, using Titanium Taq polymerase (Clontech). P18 primers are listed in Supplementary Table S1. RET primers were described in ref. 17 
Results
Generation of compound RET2B;p18, RET2B;p27 and RET2B;p18;p27 mice. To investigate the role of oncogenic RET, p18, and p27 in the multistep process of MTC development in vivo, we crossed RET2B mice (7) with p18 +/À ;p27 +/À knockout mice (18) . Mating between these mouse strains, both on a C57BL/6 background, yielded all expected genotypes at the anticipated Mendelian ratios. Reproduction was not affected in any of the generated genotypes. For this study, only mice from the third generation were used.
Wild-type mice (WT; n = 26), RET2B mice (n = 48), p18 +/À mice (n = 25), p18 À/À mice (n = 30), and p27 +/À mice (n = 22) were generated. To study the effect of oncogenic RET with additional loss of either p18 or p27 on MTC development, compound RET2B;p18 +/À mice (n = 44), RET2B;p18 À/À mice (n = 31), and RET2B;p27 +/À mice (n = 49) were generated. Franklin et al. (11) showed a synergistic effect of loss of both p18 and p27 on MTC development. To investigate a putative additional effect of oncogenic RET on loss of both p18 and p27, we generated p18 +/À ;p27 +/À mice (n = 20), p18
;p27 +/À mice (n = 24), RET2B;p18
+/À mice (n = 44), and RET2B;p18 À/À ;p27 +/À mice (n = 40). p27 À/À mice were not generated because in combination with homozygous loss of p18, they have a low mean survival of 3.5 months (11, 18) . p18 À/À mice with and without additional loss of p27 display gigantism from early ages onward (11, 18) . We did not detect any apparent enhancement of the gigantism phenotype in the presence of oncogenic RET. All mice were monitored up to 12 months of age. In this period, survival was not affected in the different genotype groups, except for p18
;p27 +/À mice, which died, or became moribund, at the age of 8 to 9 months due to previously described causes (11, 18) . The survival of compound RET2B;p18
mice was comparable to the survival of p18 À/À ;p27 +/À mice. Therefore, MTC development in the latter two genotype groups was monitored up to 9 months of age.
Synergistic effect of oncogenic RET and loss of p18 on MTC development. In RET2B mice, the expression of the oncogenic RET transgene is directed to the thyroid C-cells due to the used CALC-I promoter. These mice develop CCH and MTC without any other tumors involved in MEN2 (7) . Here, we monitored the (19) . Previously, we showed that plasma calcitonin levels can also be used to monitor MTC development in mice (7) . Blood was drawn every 3 months and when the mice became moribund. In this way, we were able to monitor MTC development and progression in time. At the time of sacrifice, thyroid glands were isolated for histologic analysis. Calcitonin immunostainings were done to identify the presence of a MTC. Bilateral and multifocal MTCs were detected in mice of different genotype groups. The level of plasma calcitonin in wild-type non-MTC-bearing mice was undetectable (Fig. 1A) . Histologic analysis revealed that in our study, plasma calcitonin levels of z1.4 pg/mL indicated the presence of a MTC (Fig. 1B) . Most MTCs were detectable only by microscopy ( Fig. 1B and C) ; however, some mice developed macroscopically detectable MTCs (Fig. 1D) .
The numbers and percentages of mice of all different genotype groups that developed MTC within 12 months are summarized in Table 1 . Up to 12 months of age, no MTC was detected in the WT, RET2B, p18 +/À , and p27 +/À groups, whereas 11% (3 of 27) of p18 À/À mice had developed MTC at this age. Forty-three percent (13 of 30) of compound RET2B;p18 À/À mice displayed MTC at 12 months, which is a significantly increased incidence compared with both RET2B mice and p18 À/À mice. The MTC incidence in RET2B;p18 À/À mice was already significantly increased to 33%
(10 of 30) at 9 months of age, indicating a strong synergistic effect of oncogenic RET and loss of p18 on MTC development. Haploinsufficiency of p18, but not p27, in RET-induced MTC. Previously, it has been shown that treatment of heterozygous p18 knockout mice with a chemical carcinogen resulted in tumor development at an accelerated rate. The remaining wild-type allele of p18 was neither mutated nor silenced in tumors derived from heterozygotes, indicating that p18 is a haploinsufficient gene in tumorigenesis in mice (20) . Although MTC developed predominantly in mice of homozygous p18 knockout groups, a subset of mice in the heterozygous p18 knockout groups did develop MTC as well. This offered an opportunity to address p18 haploinsufficiency in MTC development. As is shown in Table 1 , loss of a single p18 allele (with and without additional loss of p27) did not result in MTC development in mice up to 12 months, indicating that heterozygous loss of p18 is not sufficient for MTC development within this period. However, compound RET2B;p18 +/À mice displayed a significantly increased MTC incidence already at 9 months (21%; 9 of 42) as compared with both RET2B and p18 +/À mice, suggesting that p18 is haploinsufficient in the presence of oncogenic RET (Table 1) . RET2B mice, which had lost a single p27 allele, did not show a significant increase in MTC incidence compared with RET2B mice and p27 +/À mice: 4% (2 of 47) of RET2B;p27 +/À mice developed MTC up to 12 months of age ( Table 1 ), indicating that heterozygous loss of p27 does not affect RET-induced MTC development. These data suggest that RET and p18, but not RET and p27, cooperate in MTC development.
CCH in RET2B;p27 +/À mice and p18
;p27 +/À mice at 12 months of age. Up to 12 months of age, WT mice did not develop MTC, nor could we histologically detect CCH in these mice. The mean plasma calcitonin level of WT mice at the age of 12 months was indicated as 34,842 cps (SD, 6,466 cps; n = 25). To investigate whether mice of the different genotype groups that did not develop MTC (plasma calcitonin <100,000 cps) developed Figure 1 . MTC development in mice with elevated plasma calcitonin levels. A, calcitonin (CT ) staining on the thyroid gland of a wild-type C57BL/6 mouse with undetectable plasma calcitonin level indicating normal C-cell amounts. Right, higher magnification of the boxed area in left. B, calcitonin staining on a thyroid gland of a mouse with a plasma calcitonin level of 1.7 pg/mL indicating a micro-MTC. Right, higher magnification of the boxed area in left. C, calcitonin staining on thyroid glands of mice with plasma calcitonin levels of 2.6, 10.4, and 158 pg/mL, indicating MTCs of increasing sizes. D, macroscopic bilateral MTC (white arrows ) in a mouse with a plasma calcitonin level of 569 pg/mL. Black arrows, calcitonin-positive C-cells. f, thyroid follicle; t, trachea. Bar, 50 Am.
CCH, we analyzed whether they had significantly elevated plasma calcitonin levels at the age of 12 months (Table 2) .
Plasma calcitonin levels of RET2B mice, p18 +/À mice, and p27 +/À mice did not significantly differ from those of WT mice, suggesting that these mice did not develop CCH at the age of 12 months. P18 À/À mice, however, did develop a significant increase in plasma calcitonin at the age of 12 months (59,271 cps; SD, 17,043 cps; n = 24), suggesting CCH. In the three RET2B;p18 genotype groups in which MTC was also detected at 12 months of age, increased plasma calcitonin levels were identified in mice that did not develop MTC. Interestingly, in the RET2B;p27 +/À group and p18 +/À ;p27
group, in which MTC development could (almost) not be observed at 12 months, CCH was suggested by elevated plasma calcitonin levels compared with those of WT mice. Comparing plasma calcitonin levels of RET2B;p27 +/À mice with plasma levels of RET2B mice revealed an increase that was not significant (P = 0.06), whereas plasma calcitonin levels of p18 +/À ;p27 +/À mice were significantly (P < 0.001) increased compared with those of p18 +/À mice. These data suggest that loss of p27 synergizes with loss of p18, but not with oncogenic RET, in MTC development.
Oncogenic RET causes earlier MTC onset in compound transgenic mice. The synergism between p18 and p27 could also be observed in p18 ;p27 +/À mice (Table 1) , strongly indicating that oncogenic RET causes an earlier MTC onset in p18 À/À ;p27 +/À mice. All mice that displayed MTC already at the age of 3 or 6 months (n = 15) belonged to groups with a combined RET2B and heterozygous or homozygous p18 knockout genotype ( Table 1 ), confirming that the combination of oncogenic RET and loss of p18 strongly promotes (early) MTC development in mice.
Oncogenic RET induces larger MTCs in compound transgenic mice. As described above, oncogenic RET in combination with loss of p18 or loss of both p18 and p27 resulted in increased ND NOTE: MTC was diagnosed by plasma calcitonin levels >1.4 pg/mL. Abbreviation: ND, not determined (mice were sacrificed at 9 mo). *P = 0.001 for RET2B;p18 +/À vs RET2B; P = 0.014 for RET2B;p18 +/À vs p18 +/À . cP < 0.0001 for RET2B;p18 +/À vs RET2B; P = 0.006 for RET2B;p18 +/À vs p18 +/À . bP < 0.0001 for RET2B;p18 À/À vs RET2B; P = 0.004 for RET2B;p18 À/À vs p18 À/À .
x P < 0.0001 for RET2B;p18 À/À vs RET2B; P = 0.007 for RET2B;p18 À/À vs p18 À/À . k P = 0.269 for RET2B;p27 +/À vs RET2B; P = 0.473 for RET2B;p27 +/À vs p27 +/À . { P = 0.258 for RET2B;p27 +/À vs RET2B; P = 0.475 for RET2B;p27 +/À vs p27 +/À . **P < 0.0001 for P18 MTC incidence as well as decreased age of onset. Next, we investigated whether we could detect an effect on MTC growth of oncogenic RET, in addition to loss of p18 and p27, by comparing plasma calcitonin levels of mice with MTC. We found a correlation between plasma calcitonin levels and MTC size, as was also detected for human MTC patients ( Fig. 1C; ref. 21 ). In Fig. 2 , plasma calcitonin levels of all mice with MTC from different compound genotype groups at 3, 6, 9, and 12 months of age are indicated.
At the age of 9 months, plasma calcitonin levels of compound RET2B;p18 À/À ;p27 +/À mice with MTC (n = 24) were significantly higher (ranging from 1.4 to 569 pg/mL with a median concentration of 84.25 pg/mL; P < 0.01) compared with plasma calcitonin levels of p18 À/À ;p27 +/À mice with MTC (n = 15; ranging from 2.1 to 261 pg/mL with a median concentration of 15.6 pg/mL; Fig. 2 ). This indicates that already at 9 months of age, RET2B;p18 À/À ;p27 +/À mice have larger MTCs compared with p18 À/À ;p27 +/À mice. This was also confirmed by histologic analysis.
To investigate whether we could detect a difference in growth rate in these MTCs, we analyzed proliferation in five MTCs of both p18 À/À ;p27 +/À mice and RET2B;p18 À/À ;p27 +/À mice. The MTCs were selected from mice of each genotype group, which matched according to their plasma calcitonin levels, and thus MTCs were of comparable sizes. As determined by PCNA immunostainings and subsequent proliferation index calculations, we did not identify a significant difference (P = 0.43) in the average proliferation rates between MTCs from the two different genotype groups: 17.7% (SD, 2.4%) for MTCs from p18 À/À ;p27 +/À mice and 19.6% (SD, 4.6%) for MTCs from RET2B;p18 Table S2 ), suggesting that the larger MTCs detected in RET2B;p18;p27 mice are due to earlier age of onset rather than to increased growth rate.
Heterozygous loss of p27 increases MTC incidence in RET2B; p18 À/À , but not RET2B;p18 +/À , compound transgenic mice. As described above, heterozygous loss of p27 additionally affects MTC development in combination with complete loss of p18, but not with oncogenic RET. At 9 months of age, RET2B;p18 À/À ;p27 +/À mice displayed a significantly higher MTC incidence (100%; 26 of 26) compared with RET2B;p18 À/À mice [33% (10 of 30); Table 1 ].
In addition, RET2B;p18
;p27 +/À mice with MTC also displayed significantly higher (P < 0.001) plasma calcitonin levels compared with RET2B;p18 À/À mice with MTC (n = 10; ranging from 1.7 to 420 pg/mL with a median concentration of 2.2 pg/mL), indicating an additional effect of heterozygous loss of p27 on RET2B;p18 À/À -induced MTC development (Fig. 2) .
Comparing plasma calcitonin levels of RET2B;p18 +/À ;p27 +/À mice that did not develop MTC at the age of 12 months with plasma calcitonin levels of RET2B;p18 +/À mice revealed an increase that was not significant (P = 0.07), suggesting that additional loss of p27 does not strongly enhances CCH in RET2B;p18 +/À mice (Table 2) . Surprisingly, RET2B;p18 +/À ;p27 +/À mice (7%; 3 of 44) displayed a significantly lower MTC incidence at the age of 9 months compared with RET2B;p18 +/À mice (21%; 9 of 42), suggesting a protective effect of loss of p27 on MTC development (Table 1) . However, five of these nine RET2B;p18 +/À mice displayed plasma calcitonin levels of 1.4 to 2 pg/mL, indicating very small MTCs (Fig. 2) . Moreover, at 12 months of age, these genotype groups displayed equal frequencies of MTC development [26% (10 of 39) for RET2B;p18 +/À mice and 27% (12 of 44) for RET2B;p18 +/À ;p27 +/À mice; Table 1 ] and no significant differences (P = 0.52) in plasma calcitonin levels (Fig. 2) , indicating that it is not likely that loss of p27 is protective for MTC development. p27 is known to be a haploinsufficient tumor suppressor gene (22) . To investigate haploinsufficiency of p27 in (RET2B;)p18-induced MTC, a p27
Kip1 immunostaining was done on 41 MTCs from heterozygous p27 knockout mice (21 RET2B;p18
mice, 7 RET2B;p18 +/À ;p27 +/À mice, 11 p18
;p27 +/À mice, and 2 RET2B;p27 +/À mice). As a positive control, we stained MTC sections of two p27 +/+ mice. In none of the 41 MTCs complete loss or strongly reduced p27
Kip1 expression could be observed (not shown), indicating that the remaining p27 allele is still intact. These results indicate that p27 functions as a haploinsufficient tumor suppressor gene in p18-induced MTC tumorigenesis.
Somatic alterations in p18 or RET in murine MTCs. Next, we investigated whether we could detect loss of p18 as a somatic event in MTCs from mice without a germ-line defect in p18. We stained MTCs from seven RET2B mice (>12 months old) and from two RET2B;p27 +/À mice for p18 Ink4c . As a negative control, a p18
Ink4c immunostaining was done on MTC sections from a p18 À/À mouse (Fig. 3A) . Eight MTCs of RET2B(;p27 +/À ) mice stained positive for p18 Ink4c , whereas in one MTC of a RET2B transgenic mouse a patchy p18
Ink4c expression pattern was detected (Fig. 3B) . We could not detect homozygous loss of p18 in the DNA isolated Abbreviation: NS, not significant (P > 0.05).
RET and p18 in Multistep MTC Tumorigenesis www.aacrjournals.org from this tumor ( Supplementary Fig. S1 ). Subsequently, we carried out a mutation analysis on DNA isolated from all nine p18
MTCs. In none of these MTCs a mutation in the coding region of p18 could be detected. Coxon et al. (17) detected somatic RET mutations in four of nine MTCs from Rb;p53 double knockout mice. These RET mutations corresponded with human MEN2A-associated RET mutations. To investigate whether such mutations were acquired in MTCs from p18;p27 knockout mice as well, we carried out nucleotide sequence analysis on DNA isolated from MTCs of seven p18 À/À ;p27 +/À mice. In none of these MTCs a somatic RET mutation could be identified.
Loss of p18 Ink4c expression in MTCs from p18 +/À mice correlates with MTC progression. To assess whether p18 Ink4c expression was lost in MTCs of heterozygous p18 knockout mice, p18
Ink4c expression was determined in MTCs of RET2B;p18 +/À (n = 9) and RET2B;p18 +/À ;p27 +/À mice (n = 8). In 7 of these 17 MTCs of heterozygous p18 knockout mice, p18
Ink4c expression could be detected, comparable with p18
Ink4c expression in MTC of p18 +/+ mice. However, in 7 of these 17 MTCs, p18 Ink4c expression was completely lost, and in 3 MTCs a patchy p18
Ink4c expression pattern was observed ( Fig. 3C; Table 3 ), indicating that somatic loss of p18
Ink4c expression occurs frequently in murine MTC.
Next, we investigated whether this somatic loss of p18 Ink4c expression was due to LOH or somatic mutations in the p18 gene. In none of the MTCs that showed (partial) loss of p18
Ink4c expression could we detect loss of the wild-type p18 allele(s) ( Supplementary Fig. S1 ), nor could we detect mutations in the coding region of p18 in MTCs from these 17 RET2B;p18 +/À (;p27 +/À ) mice, indicating that other mechanisms are involved in the loss of p18
Ink4c expression in these MTCs. Furthermore, we investigated whether loss of p18
Ink4c expression affected MTC growth by comparing the plasma calcitonin levels of RET2B;p18 +/À (;p27 +/À ) mice with MTCs with (partial) loss of p18
Ink4c expression (n = 10; ranging from 6.2 to 522 pg/mL with a median concentration of 97 pg/mL) to plasma calcitonin levels of RET2B;p18 +/À (;p27 +/À ) mice with MTCs with p18 Ink4c expression (n = 7; ranging from 1.7 to 19.5 pg/mL with a median concentration of 4.8 pg/mL; Table 3 ). The plasma calcitonin levels of mice with MTCs without p18
Ink4c expression were significantly higher (P = 0.001) compared with those of mice with MTCs expressing p18
Ink4c , indicating that MTCs without p18 Ink4c expression were larger compared with those expressing p18
Ink4c . Next, we determined the proliferation rates of MTCs of RET2B;p18 Ink4c [n = 6; 11.5% (SD, 2.5%); Table 3 ]. In conclusion, loss of p18
Ink4c expression correlates with larger MTCs and higher proliferation rates, indicating that loss of p18
Ink4c enhances MTC progression.
Discussion
In this article, we provide experimental evidence that p18 inactivation functionally collaborates with oncogenic RET in murine MTC development. As compared with the single mutant mouse strains, we have found an increased MTC incidence in both RET2B;p18 +/À and RET2B;p18 À/À mice from 9 months onward.
Heterozygous loss of p27 did not result in increased MTC incidence in RET2B mice up to 12 months of age. This indicates that loss of p18, but not loss of p27, cooperates with oncogenic RET in MTC development. The observed earlier age of onset of MTC, as well as the larger MTCs, in compound RET2B;p18(;p27) mice provides further evidence for synergism between oncogenic RET and loss of p18. Furthermore, somatic loss of p18 Ink4c expression in MTCs of heterozygous p18 knockout mice resulted in higher proliferation rates and larger MTCs. Loss of p18 in the presence of oncogenic RET greatly enhances MTC incidence as well as MTC progression, which shows that loss of p18 is a frequent and severe additional oncogenic hit in RET-induced MTC tumorigenesis in mouse.
Interestingly, our results are consistent with a previously reported study about the role of p18 and p27 in MEN1 (23) . p18, but not p27, collaborates with Men1 to suppress tumor formation in pituitary, testis, thyroid, parathyroid, and pancreatic islets (23) . The synergistic effect of loss of p18 on tumor formation in both Men1 knockout mice and RET2B transgenic mice indicates a general tumor suppressor role for p18 in endocrine tissues. It has been proposed that INK4 proteins regulate the cell cycle in a cell lineage-specific manner due to tissue-specific differences in expression patterns (24) . In contrast to most other INK4 proteins, p18
Ink4c is expressed during mouse embryogenesis as well as in most adult tissues like testis, spleen, kidney, skeletal muscle, and lung (25) . Therefore, the tissue-specific effect of loss of p18 on endocrine tumorigenesis is not likely due to an endocrine-specific expression pattern of p18
Ink4c . More likely, a lack of redundancy involving the other INK4 proteins in endocrine tissues might explain the particular importance of p18 in these tissues.
Previously, biochemical studies have revealed that loss of menin, the Men1 gene product, down-regulates p18
Ink4c and p27
Kip1 expression (26, 27 Ink4c and p27 Kip1 cooperate in cell cycle arrest of different cell types (29, 30) . Loss of inhibition both early and late in G 1 (e.g., by loss of p18
Kip1
, respectively) affects cell cycle progression more severely compared with loss of inhibition early in G 1 alone (31), which could explain the differential effects observed in RET2B;p18 +/À mice and RET2B;p27 +/À mice. Different double knockout mouse models, in addition to p18;p27 knockout mice, like Rb;p53 knockout mice (16, 32) , p18;p53 knockout mice, p27;p53 knockout mice (33) , and Rb;p27 knockout mice (14) , have revealed a synergism between cell cycle regulatory genes in MTC development. This is the first time that synergism between a receptor tyrosine kinase (RET) and a CDK inhibitor (p18
Ink4c
) is reported to be involved in the ;p27 +/À mouse; middle, negative staining of a MTC of a RET2B;p18 +/À mouse; right, patchy staining of a MTC of a RET2B;p18 multistep process of MTC development. Loss of p27 in compound RET2B;p18 À/À mice further increases MTC incidence, which is not associated with loss of p27 Kip1 expression, indicating that p27 is a haploinsufficient tumor suppressor gene in p18-and RET2B;p18-induced MTC development.
Involvement of oncogenic RET in human MEN2 and MTC development is already well established. Our data suggest a cooperative role for P18 and RET in human MTC tumorigenesis. Germ-line P18 mutations have not yet been described in man, and somatic alterations in the P18 gene have rarely been detected in human cancer. However, loss of chromosome 1p32, the location of the P18 gene, is associated with both sporadic and familial MTC (8) (9) (10) . Recently, we have detected somatic inactivating P18 mutations in sporadic as well as hereditary MTCs, with a relatively high frequency compared with other types of human cancer investigated. 4 Interestingly, all somatic P18 mutations detected in human MTC coincided with germ-line or somatic RET mutations, suggesting that a cooperation between oncogenic RET and inactive P18 would also contribute to human MTC tumorigenesis.
It has been suggested that p18 is a haploinsufficient gene in mice. Haploinsufficiency of p18 has only been detected in the presence of carcinogen treatment (20) or in combination with loss of p27 or Patched (11, 34) . In our mouse models, we show that p18 functions as a haploinsufficient tumor suppressor gene in the presence of oncogenic RET. However, the haploinsufficiency of p18 is not absolute because loss of both p18 alleles resulted in a higher MTC incidence in all genotype groups and loss of p18 Ink4c expression resulted in enhanced MTC growth in p18 +/À mice. Taken together, we show that loss of p18 greatly contributes to RET-induced MTC incidence as well as MTC progression. We propose that loss of p18 (and p27) is an additional oncogenic hit in the multistep process of RET-induced MTC tumorigenesis. 
